Quarterly Activities Report and Appendix 4C Cash Flow Statement

Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea...

Related Keywords

Australia ,Monash ,South Australia ,United States ,Melbourne ,Victoria ,Australian ,George Anastassov ,Mark Bleackley ,Michael Miller ,Medchew Dronabinol ,Joel Latham ,Paul Liknaitzky ,Us National Football League ,Apirx Pharmaceutical United States Llc ,Apirx Pharmaceuticals ,Mental Health Monash ,Rx Communications Group ,Nasdaq ,Monash University Department Of Neuroscience ,International Patent Application ,Monash Trauma Group ,Monash University Turner Institute For Brain ,Prnewswire Incannex Healthcare Limited ,Corporate Governance Council Principles ,Drug Administration ,Disclosure Committee ,Incannex Healthcare ,Exchange Commission ,Monash University Human Research Ethics Committee ,Apnoea Hypopnea Index ,American Depositary Shares ,Healthcare Limited ,Monash University Department ,Football League ,Generalised Anxiety Disorder ,Monash University ,Turner Institute ,Mental Health ,World Report ,Pharmaceutical United States ,United States Securities ,Securities Litigation Reform Act ,Chief Executive ,Listing Rule ,Listing Rules ,Australian Accounting Standards ,Cash Flows ,Governance Council ,Corporate Governance Principles ,Incannex Healthcare Limited ,